13 April 2022 - NICE has published evidence based recommendations on the use of daratumumab (Darzalex) for the treatment of adults with relapsed and refractory multiple myeloma.

Daratumumab, when used as monotherapy is recommended as an option for the treatment of adults with relapsed and refractory multiple myeloma who have had a proteasome inhibitor and an immunomodulator, and whose disease progressed on the last treatment, only if:

• They use daratumumab after three treatments
• Janssen provides daratumumab according to the commercial arrangement

Read NICE appraisal guidance for daratumumab